Natera, Inc., a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus typically with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora Products of Conception test to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid in a pregnant mother's blood and a blood sample from the alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests. The company offers products through its direct sales force, as well as through a network of approximately 70 laboratory and distribution partners in the United States and internationally. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.
Industry, Sector and Symbol
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NTRA
CUSIPN/A
Phone650-249-9090
Debt
Debt-to-Equity Ratio-18.90
Current Ratio1.80
Quick Ratio1.68
Price-To-Earnings
Trailing P/E Ratio-7.53
Forward P/E Ratio-9.06
P/E GrowthN/A
Sales & Book Value
Annual Sales$210.94 million
Price / Sales4.80
Cash FlowN/A
Price / CashN/A
Book Value($0.19) per share
Price / Book-97.79
Profitability
EPS (Most Recent Fiscal Year)($2.40)
Net Income$-136,310,000.00
Net Margins-58.84%
Return on Equity-752.93%
Return on Assets-66.23%
Miscellaneous
Employees893
Outstanding Shares54,510,000
Natera (NASDAQ:NTRA) Frequently Asked Questions
What is Natera's stock symbol?
Natera trades on the NASDAQ under the ticker symbol "NTRA."
How were Natera's earnings last quarter?
Natera Inc (NASDAQ:NTRA) posted its earnings results on Tuesday, May, 8th. The medical research company reported ($0.61) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.60) by $0.01. The medical research company earned $62.34 million during the quarter, compared to analysts' expectations of $54.86 million. Natera had a negative return on equity of 752.93% and a negative net margin of 58.84%. The business's revenue for the quarter was up 26.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.70) earnings per share. View Natera's Earnings History.
What price target have analysts set for NTRA?
5 Wall Street analysts have issued 1-year price objectives for Natera's shares. Their forecasts range from $12.00 to $20.00. On average, they anticipate Natera's stock price to reach $17.00 in the next year. View Analyst Ratings for Natera.
Who are some of Natera's key competitors?
Some companies that are related to Natera include Genomic Health (GHDX), RadNet (RDNT), InVitae (NVTA), CareDx (CDNA), Veracyte (VCYT), Celcuity (CELC), Enzo Biochem (ENZ), PotNetwork (POTN), Miragen Therapeutics (MGEN), Psychemedics (PMD), Fulgent Genetics (FLGT), First Choice Healthcare Solutions (FCHS), Cancer Genetics (CGIX), Biocept (BIOC) and OpGen (OPGN).
Who are Natera's key executives?
Natera's management team includes the folowing people:
- Dr. Matthew Rabinowitz, Co-Founder, CEO, Pres & Chairman (Age 45)
- Mr. Michael Brophy, Chief Financial Officer (Age 38)
- Mr. Steve Chapman, Chief Operating Officer (Age 39)
- Mr. Jonathan Sheena, Co-Founder, Chief Technology Officer & Director (Age 45)
- Mr. Daniel Rabinowitz L.L.M., LL.M., Corp. Sec. & Gen. Counsel
When did Natera IPO?
(NTRA) raised $101 million in an initial public offering (IPO) on Thursday, July 2nd 2015. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Morgan Stanle, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and Baird and Wedbush Pacgrow were co-managers.
Has Natera been receiving favorable news coverage?
News headlines about NTRA stock have trended somewhat positive recently, according to Accern. Accern rates the sentiment of press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Natera earned a daily sentiment score of 0.08 on Accern's scale. They also gave press coverage about the medical research company an impact score of 45.95 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term.
Who are Natera's major shareholders?
Natera's stock is owned by a number of of retail and institutional investors. Top institutional investors include Sofinnova Ventures Inc (5.69%), Kornitzer Capital Management Inc. KS (1.08%), Northern Trust Corp (0.69%), Asymmetry Capital Management L.P. (0.60%), Millennium Management LLC (0.58%) and Schwab Charles Investment Management Inc. (0.32%). Company insiders that own Natera stock include Claremont Creek Partners Fund, Herm Rosenman, John Steuart, Jonathan Sheena, Matthew Rabinowitz, Michael Burkes Brophy and Steven Leonard Chapman. View Institutional Ownership Trends for Natera.
Which major investors are selling Natera stock?
NTRA stock was sold by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, Principal Financial Group Inc. and Principal Financial Group Inc.. Company insiders that have sold Natera company stock in the last year include Claremont Creek Partners Fund, John Steuart, Jonathan Sheena, Michael Burkes Brophy and Steven Leonard Chapman. View Insider Buying and Selling for Natera.
Which major investors are buying Natera stock?
NTRA stock was bought by a variety of institutional investors in the last quarter, including Sofinnova Ventures Inc, Millennium Management LLC, Asymmetry Capital Management L.P., Kornitzer Capital Management Inc. KS, Schwab Charles Investment Management Inc., A.R.T. Advisors LLC, Trexquant Investment LP and Swiss National Bank. View Insider Buying and Selling for Natera.
How do I buy shares of Natera?
Shares of NTRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Natera's stock price today?
One share of NTRA stock can currently be purchased for approximately $18.58.
How big of a company is Natera?
Natera has a market capitalization of $876.02 million and generates $210.94 million in revenue each year. The medical research company earns $-136,310,000.00 in net income (profit) each year or ($2.40) on an earnings per share basis. Natera employs 893 workers across the globe.
How can I contact Natera?
Natera's mailing address is 201 INDUSTRIAL ROAD SUITE 410, SAN CARLOS CA, 94070. The medical research company can be reached via phone at 650-249-9090.
MarketBeat Community Rating for Natera (NTRA)
MarketBeat's community ratings are surveys of what our community members think about Natera and other stocks. Vote "Outperform" if you believe NTRA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NTRA will underperform the S&P 500 over the long term. You may vote once every thirty days.
